Laura Alder, Thoracic Medical Oncologist at Duke University School of Medicine, shared a post on LinkedIn by Duke Health, adding:
“Carolina friends, please consider joining us for this conference! The Duke Cancer Network is bringing ‘Bispecifics, ADCs and Beyond: Challenges and Strategies in Clinical Implementation’ to Charlotte, NC on November 13–14, 2026, with Dr. Charlie Rudin as keynote speaker.
Leading experts will share practical, cutting-edge guidance on bispecific antibodies and antibody-drug conjugates (ADCs): covering clinical advances, toxicity management, CNS complications, and real-world community implementation. Oncologists, advanced practice providers, nurses, and pharmacists will all find high-yield takeaways.”
“Continuing Education Opportunity
Duke Cancer Network presents Bispecifics – ADCs and Beyond: Challenges and Strategies in Clinical Implementation
November 13-14, 2026, Charlotte, NC
This conference offers cutting-edge insights into emerging therapies for solid tumor cancers. Leading experts will present on clinical advances and practice use of bispecific drugs and antibody-drug conjugates (ADCs), and cover toxicity management, CNS complications, and real-world management of these drugs.
This program will provide oncologists, advanced practice providers, nurses, and pharmacists with evidence-based guidance to support community implementation of bispecifics and ADCs.
CME credit available.”
Other articles from Duke University School of Medicine on OncoDaily.